Recombinant human collagen peptide, developed based on human collagen type I, contains an arginyl‐glycyl‐aspartic acid (RGD)‐rich motif to enhance cell behavior and is anticipated as a xeno‐free polymer material for use in tissue engineering. We fabricated granules containing recombinant human collagen peptide (RCP) applied with beta‐tricalcium phosphate fine particles (RCP/β‐TCP) as bone filling scaffold material and assessed the bone forming ability of RCP/β‐TCP. Recombinant peptide was thermal crosslinked and freeze‐dried to prepare RCP. An aqueous dispersion of β‐TCP fine particles was added to RCP to obtain RCP/β‐TCP. Subsequently, RCP/β‐TCP were characterized using scanning electron microscopy (SEM), energy dispersive X‐ray spectrometry (EDX), and cell culture assessments. Furthermore, RCP/β‐TCP were implanted into rat cranial bone defects for radiographic and histological evaluations. In SEM and EDX analyses of RCP/β‐TCP, β‐TCP particles dose‐dependently covered the surface of RCP. Cell culture tests showed that RCP/β‐TCP remarkably promoted proliferation and mRNA expression of various genes, such as integrin β1 and osteogenic markers, of osteoblastic MC3T3‐E1 cells. Histomorphometric assessment at 4 weeks showed that RCP/β‐TCP significantly promoted new skull bone formation compared to RCP (p < 0.05) and control (no application) (p < 0.01). Accordingly, these findings suggest RCP/β‐TCP possess bone forming capability and would be beneficial for bone tissue engineering therapy.

中文翻译：

---

应用β-磷酸三钙微粒的重组人胶原肽颗粒的成骨能力。

基于人 I 型胶原蛋白开发的重组人胶原蛋白肽含有富含精氨酰-甘氨酰-天冬氨酸 (RGD) 的基序，可增强细胞行为，有望作为用于组织工程的无异种聚合物材料。我们制造了含有重组人胶原肽（RCP）的颗粒，并应用了β-磷酸三钙微粒（RCP/β-TCP）作为骨填充支架材料，并评估了 RCP/β-TCP 的骨形成能力。重组肽经过热交联和冷冻干燥以制备 RCP。将β-TCP细颗粒的水分散体加入到RCP中以获得RCP/β-TCP。随后，使用扫描电子显微镜 (SEM)、能量色散 X 射线光谱法 (EDX) 和细胞培养评估对 RCP/β-TCP 进行表征。此外，将 RCP/β-TCP 植入大鼠颅骨缺损处进行放射学和组织学评估。在 RCP/β-TCP 的 SEM 和 EDX 分析中，β-TCP 颗粒剂量依赖性地覆盖 RCP 表面。细胞培养试验表明，RCP/β-TCP显着促进成骨细胞MC3T3-E1细胞的多种基因的增殖和mRNA表达，如整合素β1和成骨标志物。4 周时的组织形态学评估表明，与 RCP 相比，RCP/β-TCP 显着促进了新颅骨的形成。p  < 0.05）和对照（无应用）（p  < 0.01）。因此，这些发现表明 RCP/β-TCP 具有成骨能力，将有利于骨组织工程治疗。